The National Comprehensive Cancer Network (NCCN) released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer guidelines on September 11th, 2024.
In these updates, NCCN outlines the following for the CHEK2 Ile157Thr and Ser428Phe variants as outlined in GENE-A (Page 38) ⤸
- Lower risk of breast cancer (<20%)
- High risk cancer risk management not recommended as this level of risk does not meet the risk level to warrant breast MRI
- Manage based on family history
To read more, you can check out the full guidelines by creating a FREE account at:
https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf